Quest Diagnostics Incorporated (DGX)
| Previous close | 136.94 |
| Open | 137.22 |
| Bid | 136.93 x 800 |
| Ask | 137.19 x 1100 |
| Day's range | 136.69 - 137.62 |
| 52-week range | 119.59 - 145.58 |
| Volume | |
| Avg. volume | 989,818 |
| Market cap | 15.241B |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | 18.44 |
| EPS (TTM) | 7.44 |
| Earnings date | 24 Jul 2024 - 29 Jul 2024 |
| Forward dividend & yield | 3.00 (2.19%) |
| Ex-dividend date | 05 Apr 2024 |
| 1y target est | 147.00 |
PR NewswireQuest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas on Wednesday, May 29, 2024, at 10:20 a.m. Eastern Time.
ZacksQuest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
PR NewswireQuest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).
